Immunomic Therapeutics
313 W. Liberty Street
Suite 343
Lancaster
Pennsylvania
17603
United States
Tel: 717-327-1919
Website: http://www.immunomix.com/
118 articles about Immunomic Therapeutics
-
Immunomic Therapeutics Announces Close of $61.3M Financing
4/23/2020
Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
-
Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19 Using Its Investigational UNITE Platform
4/9/2020
Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of the novel coronavirus disease caused by SARS-Cov-2 coronavirus.
-
Immunomic Therapeutics Announces Completion of Pre-IND Meeting with US FDA for ITI-1001, a Vaccine for the Treatment of GBM
3/3/2020
Meeting on ITI-1001 Phase I program for treatment of Newly-Diagnosed Glioblastoma (GBM)
-
Immunomic Therapeutics Sr. Scientist Dr. Pratima Sinha to Present at SITC-ASCO Clinical Immuno-Oncology Symposium 2020
1/27/2020
Immunomic Therapeutics, Inc. will present data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses and inhibits tumor growth when used with its investigational vaccine, ITI-4000, in mice.
-
Immunomic Therapeutics’ Collaborator, University of Florida Presents New Clinical Data from ATTAC-II Study in GBM at the 2019 Society for Neurology (SNO) Annual Meeting
11/21/2019
Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that Duane Mitchell, MD, Ph.D., a University of Florida professor of neurosurgery and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy, and his team will present new clinical data at the 2019 Society for Neurology (SNO) Annual Meeting being held in Phoenix, Arizona Nov. 20-24, 2019.
-
Immunomic Therapeutics Announces Presentations at Upcoming Scientific and Medical Conferences
11/4/2019
Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced that Immunomic scientists will present data from its oncology programs at the following scientific and medical conferences.
-
Immunomic Therapeutics to Present at the First International Symposium on Merkel Cell Carcinoma 2019
10/18/2019
Immunomic Therapeutics, Inc. will present data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses when used with its investigational UNITE vaccine, ITI-3000, in mice
-
Immunomic Therapeutics to Present at Precision Lung Cancer World R&D Summit
10/17/2019
Discussion of UNITE platform as applied in cancer immunotherapy
-
Immunomic Therapeutics Assumes Sponsorship of ATTAC-II IND for ITI-1000, a Dendritic Cell Vaccine in Phase 2 for the Treatment of GBM
10/1/2019
ITI-1000 targets CMV with Immunomic Therapeutics’ immunotherapy UNITE™ platform
-
Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board
9/10/2019
Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School Neurosurgeon-in-Chief and Chairman, Department of Neurosurgery, Brigham and Women's Hospital to its scientific advisory board.
-
Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. as VP, Clinical Development
7/12/2019
Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as VP, Clinical Development. Dr. Eisen is a translational medicine and clinical development specialist with over 20 years of experience in the biotech and pharma sectors.
-
Immunomic Therapeutics Announces Promotion of Teri Heiland, Ph.D. to Chief Scientific Officer
6/20/2019
Immunomic Therapeutics, Inc. announced the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer. In her new role, Dr. Heiland will oversee all of research and development and will play an integral role in business development and the management of ITI’s existing and future partnerships.
-
Immunomic Therapeutics to Present at China Focus @BIO Philadelphia
5/30/2019
ITI’s technology platform has the potential to utilize the body’s natural biochemistry to develop a broad immune response and is currently being employed in a Phase II clinical trial as a cancer immunotherapy.
-
Immunomic Therapeutics to Participate at Sach’s 5th Annual Immuno-oncology BD&L and Investment Forum
5/24/2019
Immunomic Therapeutics, Inc. announced that the company will present at the 5th Annual Immuno-oncology BD&L and Investment Forum being held in Chicago, IL, May 31, 2019.
-
It should be no surprise that the Washington, DC and Baltimore areas are considered strong for life sciences. This is BioSpace’s BioCapital Community Hotbed.
-
Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2019
4/4/2019
Immunomic Therapeutics, Inc. announced that it will participate at the World Vaccine Congress Washington being held in Washington, D.C. April 14-17, 2019.
-
Immunomic Therapeutics Presents Late-Breaking Preclinical Data on DNA Vaccine ITI-7000 at AACR 2019
4/2/2019
Data demonstrate that UNITE, as a nucleic acid platform, may enhance antitumor immunity
-
Immunomic Therapeutics Announces Late-Breaking Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019
2/28/2019
Immunomic Therapeutics, Inc. announced today that a poster will be presented by Immunomic scientists at the American Association for Cancer Research (AACR) Annual Meeting 2019 to be held in Atlanta, Georgia from March 29-April 3, 2019.
-
Immunomic Therapeutics to Sponsor and Present at CHCI Health Summit
2/26/2019
Immunomic Therapeutics, Inc. announced that its’ Senior Vice President and Co-Founder, Teri Heiland, Ph.D., will participate in the closing plenary on Innovation and Technology in Healthcare at the Congressional Hispanic Caucus Initiative Health Summit on March 14, 2019 at 2:00 pm EST at the Newseum, Knight Conference Center in Washington, DC.